At Avance Biosciences, we believe the best way to understand the value of our work is to see it in action. That’s why we’re excited to launch a new blog series highlighting real-world case studies where our CGMP/GLP-compliant Next-Generation Sequencing (NGS) services have helped clients overcome critical challenges across the drug development lifecycle.
Each case study in this series walks through a unique client scenario, from ensuring plasmid sequence fidelity for IND-enabling batch release to identifying unknown viral contaminants, detecting off-target gene edits, or confirming sgRNA identity in complex biologic products. You’ll get an inside look at the specific assays we designed, the technologies we used (Illumina, PacBio, rhAmpSeq, and more), and how our validated workflows delivered accurate, regulatory-ready data.
Whether you’re in early discovery, preclinical development, or preparing for regulatory submission, this series offers valuable insights into how advanced sequencing technologies are applied in real-world programs.
Make sure to follow along, new case studies will be published regularly, each offering practical solutions and lessons learned that can inform your own development strategy.
Accelerate your drug development with Avance Biosciences’ Next-Generation Sequencing (NGS) Center of Excellence, delivering GMP- and GLP-compliant genomics solutions to power your development programs. Our capabilities include Short-read Next-gen Sequencing, Nanopore Third-gen Sequencing, PacBio Third-gen Sequencing, 10X Chromium Single-cell Sequencing, and Mission Bio Tapestri Single-cell Sequencing. Learn more at our NGS Center of Excellence and contact our experts to get started.
